Skip to content
Review Open access

The Role of Gut Microbiome Modulation in the Treatment and Prevention of Obesity: A Systematic Review

Oct 2026 · Biomedical Journal of Scientific & Technical Research · 0 citations

Abstract

Obesity, affecting over 1 billion individuals globally, is a pressing public health crisis linked to metabolic disorders like diabetes and cardiovascular disease. Emerging evidence highlights the gut microbiome’s role in regulating energy metabolism, inflammation, and adiposity, positioning microbiota modulation as a novel therapeutic strategy. This systematic review evaluated the efficacy of probiotics, fecal microbiota transplantation (FMT), and dietary interventions on obesity outcomes, synthesizing 20 peer-reviewed studies (2020–2025) via PRISMA guidelines. Probiotics, particularly Bifidobacterium breve and Akkermansia muciniphila, reduced BMI by 1.2–1.8 points and improved lipid profiles (LDL-C ↓12.4 mg/dL) by restoring microbial diversity and normalising the Bacteroidota/Bacillota ratio. FMT from lean donors demonstrated sex-specific benefits, reducing visceral adiposity in women (−3.2 cm waist circumference) despite no overall BMI change. Dietary interventions, including inulin (15–30g/day) and polyphenols, enriched Bifidobacterium and Flavonifractor plautii, correlating with enhanced insulin sensitivity (HOMA-IR ↓0.20) and reduced inflammation (CRP −1.2 mg/L). However, methodological heterogeneity-variable probiotic dosing (1×10⁹–1×10¹¹ CFU/day), inconsistent sequencing methods (16S rRNA vs. shotgun metagenomics), and small sample sizes-limited cross-study comparability. While microbiome modulation shows promise, standardised protocols for interventions, microbiota analysis, and outcome metrics are critical for clinical translation. Longitudinal studies, individual microbiota profiling, and the integration of multi-omics should be given priority in future research to streamline therapeutics. The results support the role of the gut microbiome in managing obesity, promoting the idea that scalable frameworks should be developed to realise the clinical potential of the microbiome.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.